All News

A new study examining sleep irregularity and sleep duration found that sleep irregularity was associated with several indictors of heart disease.

The prevalence of comorbidities in patients with severe chronic obstructive pulmonary disease (COPD), including impaired kidney function, are predictors of long-term mortality, study finds.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.

Researchers found that only 8 of 18 HIV risk assessment models have been externally validated and show moderate-to-good discrimination ability for HIV infection prediction.

A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.

In the first keynote session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit, the history of CRISPR genome editing and its potential in cancer and other settings took center stage.

Ganglion cell/inner plexiform layer (GCIPL) and circumpapillary retinal nerve fiber layer (cpRNFL) thinning were both associated with a higher risk of developing perimetric glaucoma.

Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.

There is clearly an important role for teplizumab to treat type 1 diabetes (T1D) right now, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.

A combination of evidence-based interventions and team-based approaches shows efficacy in helping physicians care for patients with chronic obstructive pulmonary disease (COPD), according to one study.

Panelists at the keynote session of the Value-Based Insurance Design Summit highlighted what their organizations are doing in health equity.

Medicaid plans begin planning for the upcoming lapse in continuous coverage starting April 1, 2023; Bayer plans to spend $1 billion on US pharmaceutical research and development in 2023; opioids were the most common cause of death by poisoning in young children.

Given the cost and impact of chronic diseases on the US health care system, health technology like digital coaching for chronic diseases is increasingly being looked at as a way to offer personalized therapies on a wide scale.

Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital identified new targets for small molecule drugs to counter Clostridioides difficile colonization and infection (CDI) in the gut and provide a new approach to rapidly define microbial metabolism for other applications.

A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans.

The FDA approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small-cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.

Perampanel, a novel antiepileptic drug, was associated with a reduction in seizure frequency of at least 50% in more than half of children and adolescents in a meta-analysis.

How asthma and other skin conditions cluster in Black children and a finding of increased risk of respiratory infections in Black and Mexican-American children with asthma were among the studies presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) conference.

US adults had low trust in public health agency information during the COVID-19 pandemic, a new survey reported; a new study showed that people who have been incarcerated are more likely to die when they have cancer, compared to those never incarcerated; an unproven drug aimed at preventing preterm birth will be removed from the US market.

The new recommendations from the World Health Organization (WHO) urge viewing the totality of evidence when evaluating biosimilar products.

Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, spoke on financial toxicity, heterogeneity of cancer, and other complex factors in oncology care systems that may perpetuate disparities in health care outcomes and delivery among patients.

Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.

A study spanning 8 decades has found a link between infant lower respiratory tract infection and premature death from respiratory disease in adulthood.

Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.

The supplemental Biologics License Application was filed for the new indication for dupilumab, which is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

Online communities are important for individual’s facing infertility, but they should be carefully managed by professionals, a review finds.

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

Researchers found that treatment modality was associated with the proportion of youths with type 1 diabetes (T1D) achieving recommended clinical targets.

The EASIX scoring system should not be used to predict outcomes following allogeneic stem cell transplantation (alloSCT) in patients with myelofibrosis.